Common treatments among Crohn's disease and ulcerative colitis U.S. patients in 2021
In 2021, around 51 percent of Crohn's disease and ulcerative colitis patients in the United States reported using biologic or JAK inhibitors, while 24 percent stated they use an immunomodulator. This statistic illustrates common treatments among Crohn's disease and ulcerative colitis patients in the United States in 2021.